SRX Medicine

SRX Medicine / 2010 / Article

Case Report | Open Access

Volume 2010 |Article ID 581923 | 3 pages | https://doi.org/10.3814/2010/581923

Fatal Mimicry: Oral Melanoma versus Mantle Cell Lymphoma

Received15 Oct 2009
Revised18 Jan 2010
Accepted09 Feb 2010
Published30 Mar 2010

Abstract

We present a 71-year-old male with oral melanoma and mantle cell hyperplasia who was erroneously diagnosed and treated as mantle cell lymphoma. The differential diagnosis of MCL versus mantle cell hyperplasia is a challenging task. Thorough immunohistochemical and cytogenetic analyses are warranted before treatment administration. The more common presentation of amelanotic malignant melanoma requires a high index of suspicion for masses identified in the mouth and requires biopsy for definitive diagnosis. A meticulous physical examination is advocated.

References

  1. J. J. Sciubba, “Oral cancer: the importance of early diagnosis and treatment,” American Journal of Clinical Dermatology, vol. 2, no. 4, pp. 239–251, 2001. View at: Google Scholar
  2. J. L. Cebrián Carretero, M. Chamorro Pons, and N. Montesdeoco, “Melanoma of the oral cavity. Review of the literature,” Medicina Oral, vol. 6, no. 5, pp. 371–375, 2001. View at: Google Scholar
  3. R. Bovo, A. Farruggio, M. Agnoletto, M. Galceran, and F. Polidoro, “Primitive malignant melanoma of the base of the tongue,” Acta Otorhinolaryngologica Italica, vol. 16, no. 4, pp. 371–374, 1996. View at: Google Scholar
  4. M. Gorsky and J. B. Epstein, “Melanoma arising from the mucosal surfaces of the head and neck,” Oral Surgery, Oral Medicine, Oral Pathology, Oral Radiology, and Endodontics, vol. 86, no. 6, pp. 715–719, 1998. View at: Google Scholar
  5. D. D. Weisenburger, W. G. Sanger, J. O. Armitage, and D. T. Purtilo, “Intermediate lymphocytic lymphoma: immunophenotypic and cytogenetic findings,” Blood, vol. 69, no. 6, pp. 1617–1621, 1987. View at: Google Scholar
  6. D. Leroux, F. Le Marc'Hadour, R. Gressin et al., “Non-Hodgkin's lymphomas with t(11;14)(q13;q32): a subset of mantle zone/intermediate lymphocytic lymphoma?” British Journal of Haematology, vol. 77, no. 3, pp. 346–353, 1991. View at: Google Scholar
  7. R. Rimokh, F. Berger, C. Bastard et al., “Rearrangement of CCND1 (BCL1/PRAD1) 3 untranslated region in mantle-cell lymphomas and t(11q13)-associated leukemias,” Blood, vol. 83, no. 12, pp. 3689–3696, 1994. View at: Google Scholar
  8. B. Johansson, F. Mertens, and F. Mitelman, “Cytogenetic evolution patterns in non-Hodgkin's lymphoma,” Blood, vol. 86, no. 10, pp. 3905–3914, 1995. View at: Google Scholar
  9. O. Monni, R. Oinonen, E. Elonen et al., “Gain of 3q and deletion of 11q22 are frequent aberrations in mantle cell lymphoma,” Genes Chromosomes and Cancer, vol. 21, no. 4, pp. 298–307, 1998. View at: Publisher Site | Google Scholar
  10. J. Limpens, D. de Jong, J. H. J. M. van Krieken et al., “Bcl-2/JH rearrangements in benign lymphoid tissues with follicular hyperplasia,” Oncogene, vol. 6, no. 12, pp. 2271–2276, 1991. View at: Google Scholar
  11. P. Meusers, M. Engelhard, H. Bartels et al., “Multicentre randomized therapeutic trial for advanced centrocytic lymphoma: anthracycline does not improve the prognosis,” Hematological Oncology, vol. 7, no. 5, pp. 365–380, 1989. View at: Google Scholar
  12. E. Zucca, E. Roggero, G. Pinotti et al., “Patterns of survival in mantle cell lymphoma,” Annals of Oncology, vol. 6, no. 3, pp. 257–262, 1995. View at: Google Scholar
  13. I. Teodorovic, S. Pittaluga, J. C. Kluin-Nelemans et al., “Efficacy of four different regimens in 64 mantle-cell lymphoma cases: clinicopathologic comparison with 498 other non-Hodgkin's lymphoma subtypes,” Journal of Clinical Oncology, vol. 13, no. 11, pp. 2819–2826, 1995. View at: Google Scholar
  14. E. Braunwald, A. S. Fauci, D. L. Kasper, S. L. Hauser, D. L. Longo, and J. L. Jameson, Harrison's Principles of Internal Medicine, McGraw-Hill, New York, NY, USA, 15th edition, 2001.
  15. J. H. Schiller, M. J. Hawkins, M. J. O'Connell, K. Sielaff, and E. C. Borden, “A phase I trial of interferon-α-2a plus cyclophosphamide, vincristine, prednisone, and doxorubicin,” Journal of Biological Response Modifiers, vol. 8, no. 3, pp. 252–261, 1989. View at: Google Scholar

Copyright © 2010 L. Margolin and A. Monselise. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.


More related articles

69 Views | 0 Downloads | 0 Citations
 PDF  Download Citation  Citation
 Download other formatsMore
 Order printed copiesOrder

Related articles

We are committed to sharing findings related to COVID-19 as quickly and safely as possible. Any author submitting a COVID-19 paper should notify us at help@hindawi.com to ensure their research is fast-tracked and made available on a preprint server as soon as possible. We will be providing unlimited waivers of publication charges for accepted articles related to COVID-19. Sign up here as a reviewer to help fast-track new submissions.